|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Sir Andrew Witty
|
|
|
b)
|
Position/status
|
Chief Executive Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 13 October 2016.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£17.0319
|
25.344
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2016-10-13
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr R G Connor
|
|
|
b)
|
Position/status
|
President, Global Manufacturing & Supply
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 13 October 2016.
|
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£17.0319
|
30.656
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2016-10-13
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr L Debruyne
|
|
|
b)
|
Position/status
|
President, Global Vaccines
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 13 October 2016.
|
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£17.0319
|
645.478
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2016-10-13
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr S Dingemans
|
|
|
b)
|
Position/status
|
Chief Financial Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 13 October 2016.
|
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£17.0319
|
111.076
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2016-10-13
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr S A Hussain
|
|
|
b)
|
Position/status
|
President, Global Pharmaceuticals
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 13 October 2016.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£17.0319
|
589.664
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2016-10-13
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr D S Redfern
|
|
|
b)
|
Position/status
|
Chief Strategy Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 13 October 2016.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£17.0319
|
921.902
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2016-10-13
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Ms C Thomas
|
|
|
b)
|
Position/status
|
SVP, HR
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 13 October 2016.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£17.0319
|
127.956
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2016-10-13
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr P C Thomson
|
|
|
b)
|
Position/status
|
SVP, Communications & Government Affairs
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 13 October 2016.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£17.0319
|
413.464
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2016-10-13
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Dr M M Slaoui
|
|
|
b)
|
Position/status
|
Chairman, Global Vaccines
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 13 October 2016.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£17.0319
|
1.905
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2016-10-13
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Dr P J T Vallance
|
|
|
b)
|
Position/status
|
President, Pharmaceuticals R&D
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 13 October 2016.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£17.0319
|
1545.793
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2016-10-13
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Ms E Walmsley
|
|
|
b)
|
Position/status
|
CEO Designate
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 13 October 2016.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£17.0319
|
1211.674
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2016-10-13
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mrs K Thomson
|
|
|
b)
|
Position/status
|
PCA of Mr P C Thomson (SVP, Communications & Government
Affairs)
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 13 October 2016.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£17.0319
|
101.411
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2016-10-13
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|